Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01999517
Other study ID # ConanTrial
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date June 2013
Est. completion date June 2018

Study information

Verified date August 2019
Source Mt. Sinai Medical Center, Miami
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Contrast-induced nephropathy (CIN) is a complication of percutaneous coronary angiography that occurs in about 10 to 20% of patients exposed to contrast media. Iodinated contrast is used during coronary angiography to see the coronary arteries. It has been shown that exposure to this agent may cause kidney injury. CIN usually goes away on its own but in some high risk patients it progresses into renal failure.

This research study offers a new possible option to prevent CIN. We propose that if intravenous nitroglycerin is given before the procedure it may lower the chances of developing contrast-induced nephropathy.


Description:

The Contrast Nephropathy and Nitrates trial (CoNaN) is a single center, randomized, 1 x 1 factorial clinical trial designed to test the effects of intravenous nitroglycerin infusion in renal function given prior to PCI.

Specific aims for this trial include:

- To determine whether the intravenous nitrates have any effect on the glomerular filtration rate (GFR) after the exposure to contrast media.

- To determine if intravenous nitroglycerin will decrease the incidence of contrast induced Nephropathy.

400 patients with a Mehran score of > 6 and a pre-procedural creatinine measurement will be enrolled. Following baseline assessments, patients will be randomly assigned to receive intravenous infusion nitroglycerine plus intravenous normal saline or normal saline only. Subjects will participate in this study from the time they sign consent (prior to angiographic procedure), until 48-72 hours post procedure.


Recruitment information / eligibility

Status Completed
Enrollment 122
Est. completion date June 2018
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patient must be scheduled for percutaneous coronary angiography.

2. Patients must have a Mehran score more or equal to 6 before the procedure.

3. Patients must have baseline creatinine and hemoblogin drawn before the procedure.

4. Signed informed consent.

Exclusion Criteria:

1. Patients on renal replacement therapy before randomization, will be excluded.

2. Being exposed to any types of nitrates 48 hours prior to randomization,

3. History of allergic reaction to any of the components of intravenous nitroglycerin.

4. Exposure to contrast media 4 days prior randomization.

5. Planned revascularization in the next 24 to 48 hours of the first PCI procedure.

6. The patient is hypotensive (<90/60mmHg) at the time of randomization.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Intravenous Nitroglycerin

IV Fluids


Locations

Country Name City State
United States Mount Sinai Medical Center Miami Beach Florida

Sponsors (2)

Lead Sponsor Collaborator
Mt. Sinai Medical Center, Miami Florida Heart Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in GFR The primary endpoint for this trial will be to determine the change in glomerular filtration rate after exposure to contrast media. We will compare the change in GFR before and after PCI of the group that received intravenous nitroglycerin with the change in GFR before and after PCI of the group that did not receive intravenous nitroglycerin. Baseline and 48 to 72 hours post-PCI
See also
  Status Clinical Trial Phase
Completed NCT00842868 - The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases N/A
Completed NCT00634491 - Comparison Between Effect of Acetazolamide and NaHco3 in Prevention of Contrast Nephropathy Phase 2
Terminated NCT00476619 - Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial Phase 4
Recruiting NCT03121053 - Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement Phase 4
Completed NCT02650336 - Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial N/A
Completed NCT01741896 - Can Remote Ischaemic Preconditioning Reduce Contrast Induced Nephropathy in Patients Receiving Contrast for Computed Tomography? N/A
Terminated NCT00575419 - Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure Phase 1
Not yet recruiting NCT00392405 - Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate Phase 2
Completed NCT00292487 - Patients With Renal Impairment Undergoing CT Phase 4
Recruiting NCT04982419 - Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial Phase 2/Phase 3
Completed NCT00770614 - Hydration and Contrast-Induced Nephropathy in Primary Angioplasty Phase 4
Recruiting NCT00702728 - Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy (CIN) Prevention Phase 3
Completed NCT00531765 - Sodium Bicarbonate in Preventing Contrast Induced Nephropathy N/A
Completed NCT00639912 - Effects of Hydration to Prevent Contrast Induced Nephropathy in PCI for ST-elevation Myocardial Infarction. Phase 4
Terminated NCT00494637 - The Use of Sodium Bicarbonate in the Prevention of Contrast Induced Nephropathy N/A
Completed NCT02516072 - Use of Remote Ischaemic Preconditioning in the Prevention of Contrast Induced Nephropathy N/A
Active, not recruiting NCT01402232 - REduction of rIsk for Contrast Induced Nephropathy
Recruiting NCT02113540 - Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography Phase 3
Active, not recruiting NCT01456013 - Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients Phase 3
Recruiting NCT01399203 - Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention N/A